Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Inflammation and cancer share a mutualistic relationship, often driven by Signal Transducers and Activators of Transcription 3 (STAT3).
• Melatonin and salicylic acid are well-studied bioactive compounds with therapeutic potential.

Purpose of the Study:

• To design and synthesize novel melatonin derivatives targeting STAT3 to inhibit the inflammation-cancer axis.
• To evaluate the efficacy of a representative compound, P-3, in curbing inflammation-promoting cancer.

Main Methods:

• Synthesis of melatonin derivatives.
• In vitro evaluation of compound P-3's IC50 values against cancer cell lines.
• Assessment of STAT3 signaling pathway modulation (expression, activation, nuclear translocation).
• Analysis of cytokine expression and induction of apoptosis via the ROS/Cyto-c/Caspase-3 pathway.

Main Results:

• Compound P-3 demonstrated significant anti-cancer activity with IC50 values between 7.37-18.62 μM.
• P-3 effectively down-regulated STAT3 expression, activation, and nuclear translocation.
• The compound disrupted the STAT3 feedforward loop by reducing pro-tumorigenic cytokines and induced apoptosis through the ROS-triggered Cyto-c/Caspase-3 pathway.

Conclusions:

• Melatonin derivative P-3 shows potent anti-cancer properties by targeting the STAT3 pathway.
• P-3 effectively inhibits the crosstalk between inflammation and cancer.
• This study highlights P-3 as a promising scaffold for developing novel anti-cancer agents.